Showing results (81-90 of 93) with videos related to

Sort By:
Pageof 10
NPJ Parkinson'S Disease|November 30, 2021
Cerebrospinal fluid biomarkers in Parkinson's disease with freezing of gait: an exploratory analysisJ M Hatcher-Martin, J L McKay, A F Pybus, et al.
Parkinsonism & Related Disorders|March 15, 2001
The long-term safety and efficacy of pramipexole in advanced Parkinson's diseaseW J. Weiner, S A. Factor, J Jankovic, et al.
Neurology|October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystoniaM F Brin, M F Lew, C H Adler, et al.
NPJ Parkinson'S Disease|May 6, 2016
Common Genetic Variant Association with Altered HLA Expression, Synergy with Pyrethroid Exposure, and Risk for Parkinson's Disease: An Observational and Case-Control StudyG T Kannarkat, D A Cook, J-K Lee, et al.
NPJ Parkinson'S Disease|June 27, 2017
LRRK2 levels in immune cells are increased in Parkinson's diseaseD A Cook, G T Kannarkat, A F Cintron, et al.
Neurology|October 26, 1999
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystoniaA Brashear, M F Lew, D D Dykstra, et al.
Neurology|September 26, 1997
Botulinum toxin type B: a double-blind, placebo-controlled, safety and efficacy study in cervical dystoniaM F Lew, B T Adornato, D D Duane, et al.
The Pharmacogenomics Journal|October 4, 2012
A genetic basis for the variable effect of smoking/nicotine on Parkinson's diseaseE M Hill-Burns, N Singh, P Ganguly, et al.
Parkinsonism & Related Disorders|April 1, 2014
Severity of depression and anxiety are predictors of response to antidepressant treatment in Parkinson's diseaseA J H Moonen, A Wijers, A F G Leentjens, et al.
Archives of Neurology|July 25, 1998
Clinical presentation and pharmacological therapy in corticobasal degenerationK Kompoliti, C G Goetz, B F Boeve, et al.
Pageof 10